Available Until 4/24/2027

Pharmacogenomics Certificate

Release Date: April 24, 2024
Expiration Date: April 24, 2027

ACPE Numbers: Various – see below
Activity Type: Application-based/Knowledge-based
CE Contact Hour(s): 19.5 contact hours


This self-guided, online certificate will provide 19.5 hours of ACPE continuing education for pharmacists, incorporating recorded presentations, skill-focused activities, and supportive readings. 

These 8 modules are designed for participants to increase the knowledge and skills necessary to use pharmacogenomics to improve medication use in a variety of patient care settings. The curriculum addresses the rationale and process for applying pharmacogenomics in practice and covers the key considerations and challenges when implementing pharmacogenomics in a health system. Upon completion of all the modules, participants should be proficient in interpreting pharmacogenomics results, recommending appropriate patient-specific pharmacotherapy, and proactively identifying the challenges associated with pharmacogenomics implementation.

Pharmacogenomics Certificate Requirement 

Once a learner has completed the educational curriculum, they will have the opportunity to complete an online comprehensive exam. Once the learner completes the exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The activities are intended for pharmacists seeking to expand their knowledge and skills in using and implementing pharmacogenomics in their practice to ultimately improve medication use.

Learning Activity

ACPE Number

Contact Hours

Getting Started in Pharmacogenomics



Resources, Evidence, and Important Pharmacogenes



Guidelines and Informatics



Clinical Application of Pharmacogenomics Part I



Clinical Application of Pharmacogenomics Part II



Building a Pharmacogenomics Program



Taking a Real Look at Building a Program



Pulling It Together: Education, Ethics, and Next Steps



  →  Final Assessment: (80% passing score required)

Getting Started in Pharmacogenomics
ACPE: 0204-0000-24-756-H04-P
CE Hours: 2
Activity Type: Knowledge-based

  • Discuss the rationale for using pharmacogenomics to optimize medication use.
  • Identify key concepts, trends, and resources that enable pharmacogenomics to be used to optimize drug therapy.
  • Discuss how this certificate program will increase your knowledge and skills in implementing pharmacogenomics in your practice.
  • Describe how this certificate program will improve your knowledge and skills in providing patient care using a patient’s pharmacogenomics profile.
  • Define basic genomic terminology.
  • Explain general genomic concepts.
  • Define important pharmacogenomic terminology.
  • Describe pharmacogenomic testing methods. 

Resources, Evidence, and Important Pharmacogenes
ACPE: 0204-0000-24-757-H04-P
CE Hours: 1.75
Activity Type: Knowledge-based

  • Illustrate the process to assess clinical actionability of specific gene-drug pairs using medical evidence.
  • Identify appropriate frameworks to evaluate pharmacogenomic information.
  • Describe the most common pharmacogenes involved in drug metabolism.
  • Explain the relationship between genetic polymorphisms and enzyme activity.
  • Discuss gene-specific differences when interpreting pharmacogenomic results related to drug metabolism.
  • Recognize the effect of SLCO1B1 genotype on transporter function.
  • Recognize phenotype carrier status as it relates to G6PD, HLA, RYR1, CACNA1S and medications. 

Guidelines and Informatics
ACPE: 0204-0000-24-758-H04-P
CE Hours: 2.5
Activity Type: Knowledge-based

  • Discuss sections of the CPIC® guidelines and their relevance to practice.
  • Describe major pharmacogenomics guideline writing groups.
  • Identify various pharmacogenomics resources.
  • Describe the role of the various pharmacogenomics resources.
  • Apply appropriate pharmacogenomics resources to clinical cases.
  • Explain the importance of informatics to support the implementation of pharmacogenomics in clinical practice through clinical decision support.
  • Describe common informatics terms, concepts and resources for their use in pharmacogenomics. 

Clinical Application of Pharmacogenomics Part I
ACPE: 0204-0000-24-759-H01-P
CE Hours: 3.75
Activity Type: Application-based

  • Describe the utility and considerations for pharmacogenomic testing in the selection and management of antithrombotic medications.
  • Interpret evidence-based guidelines for CYP2C19 and CYP2C9, VKORC1, and CYP4F2 to guide antiplatelet agent selection and warfarin dosing.
  • Apply CYP2C19 genotyping to individualize antiplatelet agent selection in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
  • Employ available dosing tools to start anticoagulation therapy with warfarin in patients with CYP2C9, VKORC1, and CYP4F2 genotyping.
  • Interpret evidence-based guidelines for SLCO1B1, ABCG2, and CYP2C9 to guide statin dosing.
  • Describe the role of germline polymorphisms and somatic mutations in oncology.
  • Interpret genotype test results to individualize chemotherapy regimen and dosing selection.
  • Apply genotype results to individualize supportive care management in oncology patients.
  • Describe the utility and considerations for pharmacogenomic testing in the selection and management of pain medication.
  • Interpret CYP2D6 and CYP2C9 genotype results to individualize pain medication selection.
  • Recognize emerging genetic variations that may be informative for pain medication selection. 

Clinical Application of Pharmacogenomics Part II
ACPE: 0204-0000-24-760-H01-P
CE Hours: 3
Activity Type: Application-based

  • Describe the utility and considerations for pharmacogenomic testing in the selection and management of neuropsychiatric medications.
  • Interpret evidence-based guidelines for CYP2D6 and CYP2C19 to guide antidepressant therapy, including selective serotonin reuptake inhibitors and tricyclic antidepressants.
  • Apply CYP2D6 and CYP2C19 genotyping to individualize antidepressant dosing and selection.
  • Describe patient populations where testing for HLA-B*15:02, HLA-A*31:01, or CYP2C9 may be best used to guide therapeutic decision making.
  • Recognize how the results for HLA-B*15:02 and HLA-A*31:01 may differ from those of CYP2C9.
  • Propose evidence-based recommendations for patients with HLA-B*15:02, HLA-A*31:01, or CYP2C9 genetic results considering antiepileptic therapy.
  • Describe the utility of and considerations for pharmacogenomic testing in the selection and dosing of select antimicrobial agents.
  • Interpret evidence-based guidelines to guide voriconazole therapy.
  • Apply evidence-based guidelines to guide HIV drug selection.
  • Interpret evidence-based guidelines for CYP3A5 to guide tacrolimus dosing.
  • Recommend dosing adjustments for azathioprine in solid organ transplant recipients based on TPMT and NUDT15 polymorphisms.
  • Describe the utility and considerations for pharmacogenomics testing in the treatment selection for cystic fibrosis patients.
  • Discuss evidence-based recommendations for patients with HLA-B*58:01 genetic results considering allopurinol therapy. 

Building a Pharmacogenomics Program
ACPE: 0204-0000-24-761-H04-P
CE Hours: 3
Activity Type: Knowledge-based

  • Explain strategic decision points to evaluate when implementing pharmacogenomics in a health system.
  • Identify the key components and steps required for the successful implementation of pharmacogenomics in clinical practice.
  • Describe clinical pharmacogenomics service models.
  • Discuss reimbursement strategies for various care models.
  • List criteria for evaluating commercial pharmacogenomic testing laboratories.
  • Compare and contrast approaches to clinical laboratory testing in pharmacogenomics.
  • Identify essential information needed when interpreting commercial laboratory reports in pharmacogenomics.
  • Describe the key steps to incorporate pharmacogenomic information into the electronic health record with clinical decision support.
  • Discuss various approaches to use electronic tools to deliver pharmacogenomics data that enables consistent and appropriate use of results.
  • Discuss the economic value of pharmacogenomics and current perspectives of payers on preemptive pharmacogenomics. 

Taking a Real Look at Building a Program
ACPE: 0204-0000-24-762-H04-P
CE Hours: 1.5
Activity Type: Knowledge-based

  • Describe the implementation of pharmacogenomics at Cincinnati Children’s Hospital Medical Center.
  • Describe the implementation of pharmacogenomics at St. Jude Children's Research Hospital.
  • Identify strategies for implementing pharmacogenomics in an academic medical center.
  • Describe the state of pharmacogenomic implementation at NorthShore University HealthSystem.
  • Identify strategies for implementing pharmacogenomics in a community health system. 

Pulling It Together: Education, Ethics, and Next Steps
ACPE: 0204-0000-24-763-H04-P
CE Hours: 2
Activity Type: Application-based

  • Assess the level of genetic literacy of the intended audience training.
  • Choose the appropriate level of depth for the education.
  • Identify potential opportunities for further pharmacogenomics training.
  • Describe the importance and potential content of pre- and post-test counseling for pharmacogenomics.
  • Assess potential questions and areas of confusion for patients that require educational reinforcement.
  • Identify key ethical and legal implications associated with pharmacogenomic testing.
  • Discuss how pharmacogenomics can be embraced as a safety strategy.

Gillian Bell, PharmD
Clinical Pharmacist, Personalized Medicine
Mission Health
Assistant Professor of Clinical Education, Division of Practice Advancement and Clinical Education
UNC Eshelman School of Pharmacy
Asheville, North Carolina 

Henry “Mark” Dunnenberger, PharmD, BCPS
Assistant Vice President
NorthShore University HealthSystem
Evanston, Illinois 

Sonya Tang Girdwood, MD, PhD, DABCP
Assistant Professor of Pediatrics
Cincinnati Children's Hospital Medical Center
Pediatric Hospitalist, Pediatric Translational & Clinical Pharmacologist
Cincinnati, Ohio 

Cyrine E. Haidar, PharmD, BCOP, BCPS, FASHP
Associate Member
St. Jude Children’s Research Hospital
Memphis, Tennessee 

James M. Hoffman, PharmD, MS
Senior Vice President - Quality and Safety
Member, Pharmacy and Pharmaceutical Sciences
St. Jude Children’s Research Hospital
Memphis, Tennessee 

James C. Lee, PharmD, BCACP, FCCP, AACC
Clinical Associate Professor
University of Illinois Chicago College of Pharmacy
Co-Director, UI Health Precision Medicine Program
University of Illinois Hospital & Clinics
Chicago, Illinois 

Natasha J. Petry, PharmD, MPH, BCACP
Pharmacogenomics Clinical Pharmacist,
Sanford Health Imagenetics
Associate Professor of Practice,
North Dakota State University
Fargo, North Dakota 

Laura B. Ramsey, PhD
Section Chief of Individualized Therapeutics
Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation
Children’s Mercy Kansas City
Associate Professor
Department of Pediatrics
University of Missouri – Kansas City
Kansas City, Missouri

D. Max Smith, PharmD, BCPS
Clinical Pharmacogenomics Specialist
MedStar Health
Assistant Professor
Georgetown University Medical Center
Washington, DC 

Dyson T. Wake, PharmD, BCPS
Senior Clinical Specialist, Pharmacogenomics
Mark R. Neaman Center for Personalized Medicine
NorthShore University HealthSystem
Evanston, Illinois

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Henry “Mark” Dunnenberger: Veritas International, independent consultant 

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Important Note – ACPE 60 Day Deadline: 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP profile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.

The ASHP PROFESSIONAL CERTIFICATES℠ educational product line contains learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.